Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.Blood|August 21, 2008
Thalidomide and rituximab in Waldenstrom macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.Experimental Hematology|September 1, 2007
Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu miceDaniel Ditzel Santos, Allen W Ho, Olivier Tournilhac, et al.Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.Pageof 6